Anthera Pharmaceuticals Inc (ANTH.OQ)
11 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|2016||Executive Chairman of the Board|
|50||2016||President, Chief Executive Officer, Chief Operating Officer, Director|
|39||2013||Senior Vice President - Finance and Administration, Principal Accounting Officer|
|68||2016||Chief Medical Officer|
- BRIEF-Anthera Pharmaceuticals Announces Positive Outcome In The Phase 3 Result Clinical Study Of Sollpura
- BRIEF-Anthera Pharmaceuticals files for resale of up to 28.6 million shares of co's common stock
- BRIEF-ANTHERA PHARMA REPORTS Q3 LOSS PER SHARE $0.58
- BRIEF-Armistice Capital reports 5.6 percent passive stake in Anthera Pharma
- BRIEF-Anthera Pharmaceuticals announces pricing of $15 mln private placement offering